Company / EPS (Diluted)
Denali Therapeutics Inc. EPS (Diluted) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.06
FY2025
5-year range
-$2.60 / $0.63
FY2021-FY2025
Trend
+59.2%
vs FY2024
Sector context
#86 of 204
Health Care
What the data says
At $-1.06, Denali Therapeutics Inc.'s eps (diluted) ranks #86 of 204 in the Health Care sector. EPS (Diluted) returned to growth in FY2025 after 2 years of decline, reaching $-1.06.
Based on SEC 10-K filings.
-1.06 in FY2025.
Improved from $-2.39 to $-1.06 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#86 of 204 in Health CareTop 42% of 204This company -$1.06 Sector average -$0.98
▼
-8.2% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 59.2% year-over-year.
- Ranks #86 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2022.
- Lowest eps (diluted) in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.06 | +59.2% |
| FY2024 | -$2.60 | -8.8% |
| FY2023 | -$2.39 | -479.4% |
| FY2022 | $0.63 | +130.4% |
| FY2021 | -$2.07 | -430.8% |
| FY2020 | -$0.39 | +93.4% |
| FY2019 | -$5.89 | -2165.4% |
| FY2018 | -$0.26 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026